Dans le cancer du sein :
-les études menées dans les formes métastatiques
ont montré une amélioration de la réponse globa-
le et de la survie après chimiothérapie associée
aux injections d’anticorps monoclonal anti-
HER2/neu [2,18] ;
-l’élévation du taux sérique de la fraction extracel-
lulaire de HER2 (ECD/HER2) a été corrélée à un
mauvais pronostic dans les formes métastatiques,
mais non corrélée aux résultats de la chimiothéra-
pie [8].
Pour les tumeurs urothéliales, les résultats préliminaires
d’une étude de phase II associant Trastuzumab (anticorps
monoclonal recombinant contre HER2, Herceptine®) et
une poly-chimiothérapie « Gemcitabine 800 mg/m2J1-8,
Paclitaxel 200 mg/m2J1, Carboplatine AUC 5 J1» ont été
rapportés récemment chez 10 patients ayant une maladie
métastatique et ayant une surexpression de HER2/neu en
immunohistochimie [10]. Dans cette étude actuellement
en cours, une réponse partielle a été observée dans 8 cas,
dont 7 avaient des métastases viscérales. La toxicité a été
essentiellement hématologique, avec des neutropénies de
grade 3 ou 4.
1. BAJORIN DF, DODD PM, MAZUMDAR M, FAZZARI M,
MCCAFFREY JA, SCHER HI, HERR HW, HIGGINS G, BOYLE
MG. Long-term survival in metastatic transitional-cell carcinoma
and prognostic factors predicting outcome of therapy. J Clin Oncol
1999;17(10):3173-3181.
2. COBLEIGH MA, VOGEL CL, TRIPATHY D, ROBERT NJ,
SCHOLL S, FEHRENBACHER L, WOLTER JM, PATON V,
SHAK S, LIEBERMAN G, SLAMON DJ. Multinational study of
the efficacy and safety of humanized anti-HER2 monoclonal anti-
body in women who have HER2-overexpressing metastatic breast
cancer that has progressed after chemotherapy for metastatic disea-
se. J Clin Oncol 1999;17(9):2639-2648.
3. CULY CR, CLEMETT D, WISEMAN LR. Oxaliplatin. A review of
its pharmacological properties and clinical efficacy in metastatic
colorectal cancer and its potential in other maligancies. Drugs
2000;60(4):895-924.
4. DE WIT R, BOCHNER BH, SCHER HI. Treatment for metastatic
urothelial cancer. American Society of Clinical Oncology - 2001
Educational Book 2001:226-245.
5. DODD PM, MCCAFFREY JA, HILTON S. Phase I evaluation of
sequential doxorubicin gemcitabine (AG) then ifosfamide, pacli-
taxel, and cisplatin (ITP) for patients with unresectable or metasta-
tic transitional cell carcinoma of the urothelial tract. J Clin Oncol
1999;18(4):840-846.
6. FORNIER MN, SEIDMAN AD, THEODOULOU M,
MOYNAHAN ME, CURRIE V, MOASSER M, SKLARIN N,
GILEWSKI T, D’ANDREA G, SALVAGGIO R, PANAGEAS KS,
NORTON L, HUDIS C. Doxorubicin followed by sequential pacli-
taxel and cyclophosphamide versus concurrent paclitaxel and cyclo-
phosphamide: 5-year results of a phase II randomized trial of adju-
vant dose-dense chemotherapy for women with node-positive breast
carcinoma. Clin Cancer Res 2001;7(12):3934-3941.
7. GELLER N, STERNBERG CN, PENENBERG D, SCHER HI,
YAGODA A. Prognostic factors for survival of patients with advan-
ced urothelial tumors treated with methotrexate, vinblastine, doxo-
rubicin, and cisplatin chemotherapy. Cancer 1991;67(6):1525-1531.
8. HAYES DF, YAMAUCHI H, BROADWATER G, CIRRINCIONE
CT, RODRIGUE SP, BERRY DA, YOUNGER J, PANASCI LL,
MILLARD F, DUGGAN DB, NORTON L, HENDERSON IC,
CANCER AND LEUKEMIA GROUP. Circulating HER-2/erbB-
2/c-neu (HER-2) extracellular domain as a prognostic factor in
patients with metastatic breast cancer: Cancer and Leukemia Group
B Study 8662. Clin Cancer Res 2001;7(9):2703-2711.
9. HRYNIUK WM. Integrating the concept of dose-intensity into a
strategy for systemic therapy of malignant disease. Prog Clin Biol
Res 1990;354 B:93-101.
10. HUSSAIN M, SMITH DC, AL-SUKHUN S, VAISHAMPAYAN U,
PETRYLAK DP. Preliminary results of HER-2/neu screening and
treatment with trastuzumab (Herceptin)(T), paclitaxel (P), carbopla-
tin (C) and gemcitabine (G) in patients with advanced urothelial
cancer. Proc Am Soc Clin Oncol 2002;21:Abstr 800.
11. JIMENEZ RE, GRIGNON DJ, VAISHAMPAYAN U. Analysis of
HER2/neu overexpression in primary and metastatic transitional
cell carcinoma of the bladder. Proc Am Soc Clin Oncol
2000;19:329a (Abstr 1294).
12. LOEHRER PJ, EINHORN LH, ELSON PJ, CRAWFORD ED,
KUEBLER P, TANNOCK I, RAGHAVAN D, STUART-HARRIS
R, SAROSDY MF, MOWE BA. A randomized comparison of cis-
platin alone or in combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol 1992;10(7):1066-1073.
13. MALUF F, HILTON S, MAZUMDAR M. Sequential doxorubi-
cin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP)
chemotherapy (AG-ITP) in patients with metastatic or locally
advanced transitional cell carcinoma of the urothelium. Proc Am
Soc Clin Oncol 2000;19:342a (Abstr 1344).
14. NORTON L, SIMON R. The Norton-Simon hypothesis revisited.
Cancer Treat Rep 1986;70(1):163-169.
15. N O RTON L, SIMON R, BRERETON HD, BODGDEN AE.
Predicting the course of Gompertzian growth. Nature
1976;264(5586):542-545.
16. PETRYLAK DP, SCHER HI, REUTER V. P-glycoprotein (PGP)
expression in invasive and metastatic urothelial tract cancer (UTC).
Proc Am Soc Clin Oncol 1992;11:(Abstr 200).
17. SAXMAN SB, PROPERT KJ, EINHORN LH, CRAWFORD ED,
TANNOCK I, RAGHAVAN D, LOEHRER PJ, TRUMP DL. Long-
term follow-up of a phase III intergroup study of cisplatin alone or
in combination with methotrexate, vinblastine, and doxorubicin in
patients with metastatic urothelial carcinoma: A cooperative group
study. J Clin Oncol 1997;15(7):2564-2569.
18. SLAMON DJ, LEYLAND-JONES B, SHAK S, FUCHS H, PATON
V, BAJAMONDE A, FLEMING T, EIERMANN W, WOLTER J,
PEGRAM M, BASELGA J, NORTON L. Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic breast can-
cer that overexpresses HER2. N Engl J Med 2001;344(11):783-792.
19. STERNBERG CN, DE MULDER PH, SCHORNAGEL J.
Randomized phase III trial in advanced urothelial tract tumors of
high dose-intensity M-VAC chemotherapy and G-CSF versus clas-
sic M-VAC. Proc Am Soc Clin Oncol 2000;19:329a (Abstr 1292).
20. VOLLMER RT, HUMPHREY PA, SWANSON PE, WICK MR,
HUDSON ML. Invasion of the bladder by transitional cell carcino-
ma: its relation to histologic grade and expression of p53, MiB-1, c-
erb B-2, epidermal growth factor receptor, and bcl-2. Cancer
1998;82(4):715-723.
21. WITTE RS, ELSON PJ, BONO B, KNOP R, RICHARDSON RR,
DREICER R, LOEHRER PJ. Eastern Cooperative phase II trial of
ifosfamide in the treatment of previously treated advanced urothe-
lial carcinoma. J Clin Oncol 1997;15(2):589-593.
RÉFÉRENCES
985